MASH represents a significant health burden, with one in three people with overweight or obesity worldwide affected
But maximum weight loss is not always the deciding factor
Due to higher rates of relapse observed with SOF/VEL treatment in GT3-infected patients with NS5A polymorphisms, particularly those with Y93H (20% [3/15] relapse rate[22]), pretreatment testing for the presence of Y93H is recommended when using this regimen for patients with treatment experience and/or cirrhosis.[12, 13] Coadministration of RBV with SOF/VEL is recommended: if a patient has prior SOF-containing therapy experience, if Y93H is present upon testing,[12, 13] or regardless of baseline polymorphism testing for patients with both treatment experience and cirrhosis.[12] Similarly, among GT3-infected patients with treatment experience and/or cirrhosis, RBV coadministration is recommended when using the combination of SOF plus DCV in patients with baseline Y93H or regardless of baseline polymorphism testing for patients with both prior treatment experience and compensated cirrhosis
Behavior change takes belief
Across the trials, when people stop the medication, the weight tends to come back, on the order of two-thirds of what was lost within a year
Yes, you can eat pasta whilst taking Wegovy